Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.

Sucralose exposure common in healthy young adults

20 Apr 2017

Instructions to avoid low-calorie sweeteners (LCSs) are ineffective, according to a study, adding that nondietary sources such as personal care products may significantly contribute to overall exposure.

Researchers enrolled a total of 18 healthy “nonconsumers” (<1 food or beverage with LCSs/mo; aged 18 to 35 years) in a 2-week trial that assessed the effects of LCSs on the gut microbiota and consisted of three visits.

Participants were advised extensively about avoiding LCSs at baseline. After the run-in, they were randomized to consume diet soda containing sucralose or carbonated water (control) three times per day for 1 week. Participants kept food diaries throughout the study, and a spot urine sample was taken at each visit.

“Despite the selection of healthy volunteers with minimal reported LCS consumption, more than one-third were exposed to sucralose at baseline and/or before randomization, and nearly half were exposed after assignment to the control,” researchers said.

There were eight participants who had sucralose in their urine (29.9 to 239.0 ng/mL; mean 111.4 ng/mL) at baseline. After the run-in, sucralose was detected in eight individuals, two of whom did not have detectable sucralose at baseline (25.0 to 1,062.0 ng/mL; mean 191.7 ng/mL). Only one participant reported consuming an LCS-containing food prior to her visit.

After the intervention, sucralose was found in three individuals randomized to receive carbonated water (26 to 121 ng/mL; mean 60.7 ng/mL).

LCSs are found in many foods and beverages, but consumers may not be aware of their presence. Also, the role of LCSs in appetite, weight and health remains controversial, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.